NICE Technology Appraisal Guidance No 103 Etanercept and efalizumab for adults with psoriasis
The following NICE appraisal has been considered by NHS Quality Improvement Scotland through its revised procedure of processing of NICE appraisals (http://www.nhshealthquality.org/nhsqis/files/NICE%20Guidance%20process%20.pdf):
NICE Technology Appraisal Guidance No 103 - Etanercept and efalizumab for the treatment of adults with psoriasis Web Reference for Guidance and other related documents: http://www.nice.org.uk/page.aspx?o=TA103
NHSScotland should note that:
NHS Quality Improvement Scotland advises that this NICE appraisal is as valid for Scotland as for England and Wales and that the guidance on efalizumab supersedes the advice issued by the Scottish Medicines Consortium 10 December 2004. Section 6.2 of the NICE guidance recommends support for the UK wide registry for biological treatments in psoriasis (BADBIR) which is due to become active January 2007. NHSScotland should take account of the NICE appraisal and this NHS Quality Improvement Scotland email in its planning, funding and provision of services to ensure that recommended drugs or treatments are made available to meet clinical need. NHS Quality Improvement Scotland advice represents the evidence-based view of NHS Quality Improvement Scotland. This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. No other publications on the NICE appraisal will be issued by NHS Quality Improvement Scotland. A copy of the NICE appraisal is attached for your information. It includes a section on "implications for the NHS" which you may find helpful in assessing the likely impact of the health technology locally. Additionally, an easy to read summary of the guidance, called 'understanding NICE guidance" is published on the NICE website to provide information for patients and the public. Hard copies of the NICE appraisals are available from NHS Quality Improvement Scotland (contact Shonagh Buchanan, tel 0141 225 6993 or email [email protected]) and all NICE appraisals and NHS Quality Improvement Scotland advice are available on the NHS Quality Improvement Scotland website (www.nhshealthquality.org)
The following NICE appraisal has been considered by NHS Quality Improvement Scotland through its revised procedure of processing of NICE appraisals (http://www.nhshealthquality.org/nhsqis/files/NICE%20Guidance%20process%20.pdf):
NICE Technology Appraisal Guidance No 103 - Etanercept and efalizumab for the treatment of adults with psoriasis Web Reference for Guidance and other related documents: http://www.nice.org.uk/page.aspx?o=TA103
NHSScotland should note that:
NHS Quality Improvement Scotland advises that this NICE appraisal is as valid for Scotland as for England and Wales and that the guidance on efalizumab supersedes the advice issued by the Scottish Medicines Consortium 10 December 2004. Section 6.2 of the NICE guidance recommends support for the UK wide registry for biological treatments in psoriasis (BADBIR) which is due to become active January 2007. NHSScotland should take account of the NICE appraisal and this NHS Quality Improvement Scotland email in its planning, funding and provision of services to ensure that recommended drugs or treatments are made available to meet clinical need. NHS Quality Improvement Scotland advice represents the evidence-based view of NHS Quality Improvement Scotland. This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. No other publications on the NICE appraisal will be issued by NHS Quality Improvement Scotland. A copy of the NICE appraisal is attached for your information. It includes a section on "implications for the NHS" which you may find helpful in assessing the likely impact of the health technology locally. Additionally, an easy to read summary of the guidance, called 'understanding NICE guidance" is published on the NICE website to provide information for patients and the public. Hard copies of the NICE appraisals are available from NHS Quality Improvement Scotland (contact Shonagh Buchanan, tel 0141 225 6993 or email [email protected]) and all NICE appraisals and NHS Quality Improvement Scotland advice are available on the NHS Quality Improvement Scotland website (www.nhshealthquality.org)